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Abstract
Background: Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab
prophylaxis may be different between countries, especially in “otherwise healthy” late preterm infants.
Methods: We analyzed an Italian database of young children referred to emergency departments for acute lower
respiratory tract infection (ALRI) during the RSV season over a four year period, when the use of palivizumab as
prophylaxis for RSV disease was not widespread in premature infants. The demographic and environmental
characteristics and the RSV positivity (RSV+) in hospitalized and not-hospitalized patients were compared. In the
data analysis we divided children according to their chronologic age (age) and their week gestational age (wGA).
Results: Out of the 100 children evaluated, 68 were infants (≤12 month-age): 7.5 and 20.6 % were in
the <29 and 29- < 32 wGA groups respectively, and 72.0 % in the 32- < 35 wGA group. Positive
hospitalized-to-not-hospitalized ratios were found in all three wGA groups, progressively decreasing (from
4.0 to 1.2), with increasing wGA (p = 0.35). The percentage of hospitalized infants that were also RSV+ was
also progressively decreasing (from 40.0 to 28.6 % and 18.4 %) with increasing wGA (p = 0.43). In the
>12 month-age group (N = 32), there was positive hospitalized-to-not-hospitalized ratio only in the <29
wGA group with a low RSV+ frequency (<29 %) in all wGA groups. In the ≤12 month-age
group, 41 infants were evaluated with a ≤6 month-age and 27 with a >6–12 month-age. A positive
hospitalized-to-not-hospitalized ratios was found in all wGA groups in ≤6 month-age infants, despite a low
RSV+ frequency in the 29- < 32 and 32- < 35 wGA group. In the >6-12 month-age group, all infants with a
<29 and 29- < 32 wGA were hospitalized with a relatively high RSV+ frequency whilst the 32- < 35 wGA
group showed a negative hospitalized-to-not-hospitalized ratio with a lower RSV+ frequency.
Conclusions: The hospitalized-to-not-hospitalized ratios and RSV+ frequency in the first 12 months of age
in infants born prematurely confirm the vulnerability of these children for clinically important RSV infection,
most notably in the <32 wGA category.
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Background
Respiratory syncytial virus (RSV) is the single most im-
portant cause of acute lower respiratory tract infection
(ALRI) in infants and young children worldwide and, in
these target populations, bronchiolitis due to RSV is
associated with significant morbidity and, sometimes,
mortality [1]. In industrialized countries there is a com-
mon belief that RSV is primarily a serious agent in
infants and the disease is generally less common and
severe in older children [1–3]. Almost all children are
infected by RSV by 2 years of age, 60–70 % are
infected in the first year of age and, of these, 2–3 %
are hospitalized for bronchiolitis induced by RSV [3–5].
Some children are at risk for disease progression to
respiratory failure, mechanical ventilation, and intensive
care unit management. In a study performed in
Switzerland over a 4-year period (2001–2005) it was
shown that RSV-induced bronchiolitis led to the inter-
mediate or intensive care admission of approximately
1–2 % of each annual birth cohort [6]. In a revision of
data collected from 24 pediatric intensive care units
(PICUs) in France, it was found that 76 % of the 467
young children hospitalized for bronchiolitis were RSV
positive: over one-third required noninvasive ventilation
and/or mechanical ventilation, and six infants died [7].
To date, there is no effective treatment for RSV-
induced bronchiolitis: the mainstay of therapy is sup-
portive care and the possible role of any pharmaco-
logical approach is still debated. Environmental
preventive measures minimize viral transmission in hos-
pital, in the outpatient setting and at home, whilst the
only pharmacological prophylaxis is based on passive
immunoprophylaxis with palivizumab, the specific anti-
RSV humanized monoclonal antibody proven to be ef-
fective in reducing the overall hospitalization rate in
specific categories of children at risk during the RSV
epidemic period [8]. In infants without pre-existing spe-
cific medical conditions, the two major factors increas-
ing the risk of severe RSV-induced bronchiolitis are
preterm birth and young chronological age at the start
of the RSV season [9–11]. Incidence and severity of
RSV disease and significance of risk factors can vary
substantially from year to year in any one setting [11].
In an effort to ensure optimal balance of benefit and
cost, clinical guidelines are country specific and vary
with regard to their recommendations for use of palivi-
zumab prophylaxis, most clinical guidelines recom-
mending that premature infants receive prophylaxis at
the start of the RSV season. However, because of differ-
ent social and epidemiological factors, the eligibility cri-
teria to receive palivizumab prophylaxis at the start of
the RSV season are often different between countries,
especially when it comes to the “otherwise healthy” late
preterm infants [12–15].
Using the historical database of an Italian
epidemiological report on hospitalizations during
four RSV epidemic seasons [16], we aimed to evalu-
ate the demographic and environmental characteris-
tics and the RSV positivity (RSV+) of hospitalized
and not-hospitalized children during a period (2000–
2004) when palivizumab prophylaxis was not wide-
spread in premature infants. In the data analysis
children were divided according to their chronologic
age (age) and their week gestational age (wGA).
Methods
Populations
The historical database of patients included in the “Osser-
vatorio” study on the epidemiology of RSV infection in chil-
dren in Italy was analyzed. The study was performed in
years when the use of palivizumab in premature infants
was not widespread [14]. The inclusion criteria used to se-
lect and evaluate patients are reported in Fig. 1. Palivizu-
mab prophylaxis was an exclusion criterion in the study
protocol. The study protocol of the Osservatorio study was
originally approved by the Institutional Review Board of
the Department of Pathology and Laboratory Medicine,
University of Parma, Parma, Italy and written informed
consent was sought from parents or guardians of all evalu-
ated children. Nasal secretion samples were sent to the
microbiology laboratory of each hospital to check for RSV
by an immunoenzymatic test (TestPack RSV, Abbott, Italy)
within 24h. Other respiratory viruses were not tested.
Fig. 1 Number of children from the “Osservatorio” database that
were firstly analyzed and then included in the sets of analysis, to
evaluate the characteristics and the distribution of RSV positivity
(RSV+) in hospitalized and not hospitalized children belonging to
different wGA groups
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The “Osservatorio” database
This study aimed to describe the time-related pat-
tern of RSV epidemics in Italy, across four consecu-
tive epidemics, from 2000 to 2004 [16]. Data were
collected on 2241 consecutive children, aged ≤4 years,
referred to the emergency departments of 16 tertiary
care hospitals (8 centers, during the first season, 14,
during the second season and 13, during the third
and fourth seasons) for acute respiratory infection,
one day of the week (Tuesday), during the expected
RSV-epidemiological seasons (October - April). The
decision to admit a child to inpatient care was made
by local physicians responsible for each child’s care
who were not involved in the study. This database
collected information on both hospitalized and non-
hospitalized children.
Data analysis
The demographic and environmental characteristics
and the distribution of RSV positivity were compared
in children born in three different wGA: <29 wGA,
29- < 32 wGA, and 32- < 35 wGA. Children with
missing values (i.e. date of birth, wGA at birth, date
of hospitalization) were excluded from the analysis
(Fig. 1). Age at enrollment, birth order, educational
levels of the mother and of the father, day-care at-
tendance, exposure to environmental tobacco smoke,
and data pertaining to breast feeding were catego-
rized before the bivariate analysis [11, 16]. Since
some information was missing in the original data-
base, the available data for each variable are reported
in tables.
Statistical analysis
Descriptive statistics of the characteristics of the pa-
tients were performed and reported in terms of
absolute frequencies and percentages for the qualita-
tive variables. Comparison of frequency data was
performed by chi-square test or by Fisher’s exact test
in case of expected frequencies less than five. All
tests were two-sided and P-values less than 0.05
were considered statistically significant. The statis-
tical packages used were the “Statistica release 6”
(Stat Soft Corp., Tulsa, OK, USA).
Results
Demographic and environmental characteristics of the
study population
One hundred children fulfilled the criteria to be ana-
lyzed (Fig. 1). The demographic and characteristics
of the hospitalized and not hospitalized children, as
well as the factors known to increase the risk of
hospitalization for RSV-induced ALRI, are shown in
Table 1. The risk factors associated with hospitalization
for RSV-induced ALRI are reported in Tables 2 and 3, for
hospitalized and not hospitalized children, respectively.
The presence of other risk factors known to increase the
risk of hospitalization for RSV-induced ALRI was not
different among the three wGA groups.
Hospitalization and RSV+ in children evaluated with a
chronological age of ≤12 or >12–24 months
Of the 100 premature infants referred to the emer-
gency departments for ALRI, 68 were evaluated
when they were ≤12 month of age: 7.4 % in the <29
wGA, 20.6 % in the 29- < 32 wGA and 72.1 % in the
32- < 35 wGA groups (Fig. 2a). Forty one (60.3 %) of
these infants were hospitalized and the hospitalized-
Table 1 Demographic characteristics and presence of major risk







[No. (row %)] [No. (row %)]
No 55 45 -
Male gender 24 (51.06 %) 23 (48.94 %) 0.51
wGA at birth
GA < 29 w 7 (77.78 %) 2 (22.22 %) 0.32
GA 29 - <32 w 12 (57.14 %) 9 (42.86 %)
GA 32 - <35 w 36 (51.43 %) 34 (48.57 %)
Birth order (No. = 96)
1 21 (53.85 %) 18 (46.15 %) 0.82
> 1 32 (56.14 %) 25 (43.86 %)
Educational level of the mother (No. = 32)
Junior high
school
8 (80 %) 2 (20.00 %) 0.25
High school 13 (59.09 %) 9 (40.91 %)
Educational level of the father (No. = 92)
Junior high
school
22 (46.81 %) 25 (53.19 %) 0.055
High school 30 (66.67 %) 15 (33.33 %)
CHD 2 (100 %) 0 0.30
BPD 5 (55.56 %) 4 (44.44 %) 0.93
Day-care attendance (No. = 99)
Yes 4 (36.36 %) 7 (63.64 %) 0.17
No 51 (57.95 %) 37 (42.05 %)
Exposure to ETS (No. = 98)
Yes 33 (57.89 %) 24 (42.11 %) 0.68
No 22 (53.66 %) 19 (46.34 %)
Breast feeding (No. = 24)
Yes 3 (30 %) 7 (70 %) 0.52
No 6 (42.86 %) 8 (57.14 %)
GA gestational age, w weeks, mo months, ETS environmental tobacco smoke
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to-not-hospitalized ratio tended to progressively
decrease with increasing wGA, being 4.0, 2.5 and
1.2, respectively in the three wGA groups (p = 0.35)
(Fig. 2a). The percentage of hospitalized infants that
were also RSV+ was also progressively decreasing
with increasing wGA, being 40.0, 28.6 and 18.4,
respectively in the three wGA groups (p = 0.43)
(Fig. 2b). Of the 32 children evaluated who were
>12 months of age, 12.5 % were in the <29 wGA,
21.9 % in the 29- < 32 wGA and 65.6 % in the 32- <
35 wGA groups (Fig. 2c). Fourteen (43.7 %) of these
infants were hospitalized and the hospitalized-to-not-
hospitalized ratio was positive in the <29 wGA
group (3) but not in the 29- < 32 and 32- < 35 wGA
groups (0.4 and 0.7) (p = 0.32) (Fig. 2c). The low
hospitalization numbers and hospitalized-to-not-hos-
pitalized ratios were associated with a low RSV+
frequency in the <29 and 29- < 32 wGA groups, and
no RSV+ hospitalized infants in the 32- < 35 wGA
group (p = 0.04) (Fig. 2d).
Hospitalization and RSV+ in children evaluated with a
chronological age of ≤6 or >6–12 months
The data related to the 68 infants evaluated with a
≤12 month age, were then divided in two subgroups,
those with a ≤6 month age and those with a 6- ≤
12 month age. Out of the 41 (60.3 %) infants with a
≤6 month age, 4.9 % belonged to the <29 wGA
group, 24.4 % to the 29- < 32 wGA group and 70.7 %
to the 32- < 35 wGA group (Fig. 3a). Positive
hospitalized-to-not-hospitalized ratios were detected
in all wGA groups, 1.0, 1.5 and 1.6, respectively, with
no statistically significant difference (p = 0.94) (Fig. 3a)
despite a low RSV+ frequency in the hospitalized in-
fants, belonging to the 29- < 32 and 32- < 35 wGA
groups (20.0 and 24.1, respectively) (Fig. 3b).
In the >6-12 month-age group, all infants with a <29
and 29- < 32 wGA were hospitalized (Fig. 3c); a relatively
high RSV+ frequency was detected, mainly in the 29- <
32 wGA group (Fig. 3d). In contrast, in the 32- < 35
wGA group the hospitalized-to-not-hospitalized ratio
was negative with a relatively low RSV+ frequency.
Table 2 Distribution of demographic characteristics and risk
factors in hospitalized pts





[No. (row %)] [No. (row %)] [No. (row %)]
No. 7 (12.73 %) 12 (21.82 %) 36 (65.46 %) -
Male gender 4 (16.67 %) 5 (20.83 %) 15 (62.50 %) 0.51
Birth order (No. = 53)
1 4 (19.05 %) 6 (28.57 %) 11 (52.38 %) 0.13
> 1 2 (6.25 %) 5 (15.63 %) 25 (78.13 %)
Educational level of the mother (No. = 21)
Junior high school 1 (12.50 %) 2 (25.00 %) 5 (62.50 %) 0.78
High school 1 (7.69 %) 2 (15.38 %) 10 (76.92)
Educational level of the father (No. = 52)
Junior high school 4 (18.18 %) 3 (13.64 %) 15 (68.18 %) 0.43
High school 3 (10.00 %) 8 (26.67 %) 19 (63.33 %)
CHD 0 0 2 (100.00 %) 0.62
BPD 3 (60.00 %) 1 (20.00 %) 1 (20.00) 0.004
Day-care attendance
Yes 0 0 4 (100.00 %) 0.32
No 7 (13.73 %) 12 (23.53 %) 32 (62.75 %)
Exposure to ETS
Yes 4 (12.12 %) 7 (21.21 %) 22 (66.67 %) 0.97
No 3 (13.64 %) 5 (22.73 %) 14 (63.64 %)
Breast feeding (No. = 9)
Yes 0 2 (66.67 %) 1 (33.33 %) 0.08
No 0 0 6 (100 %)
CHD congenital heart disease, BPD bronchopulmonary dysplasia,
ETS environmental tobacco smoke
Table 3 Distribution of demographic characteristics and risk
factors in not hospitalized pts





[No. (row %)] [No. (row %)] [No. (row %)]
No. 2 (4.44 %) 9 (20.00 %) 34 (75.56 %) -
Male gender 1 (4.35 %) 4 (17.39 %) 18 (78.26 %) 0.90
Birth order (No. = 9)
1 0 5 (27.78 %) 13 (72.22 %) 0.34
> 1 2 (8 %) 4 (16 %) 19 (76 %)
Educational level of the mother (No. = 11)
Junior high school 1 (50.00 %) 1 (50.00 %) 0 0.02
High school 0 1 (11.11 %) 8 (88.89 %)
Educational level of the father (No. = 40)
Junior high school 2 (8.00 %) 5 (20.00 %) 18 (72.00 %) 0.50
High school 0 4 (26.67 %) 11 (73.33 %)
CHD 0 0 0
BPD 1 (25.00 %) 1 (25.00 %) 2 (50.00) 0.10
Day-care attendance (No. = 44)
Yes 0 3 (42.86 %) 4 (57.14 %) 0.25
No 2 (5.41 %) 6 (16.22 %) 29 (78.38 %)
Exposure to ETS (No. = 43)
Yes 1 (4.17 %) 4 (16.67 %) 19 (79.17 %) 0.72
No 1 (5.26 %) 5 (26.32 %) 13 (68.42 %)
Breast feeding (No. = 15)
Yes 0 2 (28.57 %) 5 (71.43 %) 0.51
No 1 (12.50 %) 1 (12.50 %) 6 (75 %)
CHD congenital heart disease, BPD bronchopulmonary dysplasia,
ETS environmental tobacco smoke
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Discussion
Because of the high social and financial healthcare
burden and the difficulties in developing safe, clinic-
ally effective and financially affordable therapeutic
measures, understanding the characteristics and the
impact of neonatal RSV infection is important in
planning preventive strategies. Prophylaxis with pali-
vizumab is the only preventive measure available to
reduce the incidence of RSV-induced hospitalizations
in high-risk infants [17]. Although recent reports
have consistently shown that RSV hospitalizations
for premature children is highest in the first year of
age [4–7, 17–24], very few studies have identified
the chronological and gestational ages of RSV-
specific hospitalizations more precisely in different
nations [4, 18, 23, 24]. Because of different social
and epidemiological factors, the eligibility criteria to
receive palivizumab prophylaxis may be different in
different countries, especially in late preterm infants.
In evaluating the Osservatorio database, we found that,
consistent with premature infants in the general popula-
tion, most of the children evaluated in the four RSV sea-
sons were in the 32- < 35 wGA group [25]. This was true
in the infants enrolled both in the first and in the second
year of age. However, in the first year of age, the
hospitalized-to-not hospitalized ratio was positive in all
three wGA groups, progressively decreasing with in-
creasing wGA. A similar trend was observed for RSV+
Fig. 2 Data from the “Osservatorio” database: comparison between hospitalized (H+) and not hospitalized (H−) children. a On the
ordinate, the number of H+ and H− infants evaluated with a chronological age ≤12 months (mo) are shown and, on the abscissa, the
three weeks’ gestational age (wGA) groups. The H+-to- H− ratios in the three wGA groups are also included in the figure (*). b On the
ordinate the percentage of H+ and H− infants that were RSV+ or RSV- are shown and, on the abscissa, the three wGA groups. c and
d. The same data in children evaluated with a chronological age >12–24 mo are shown. In the two chronological age groups, panels
a and c, the tendency of the hospitalized-to-not-hospitalized ratio to progressively decrease with increasing wGA did not reach the
statistically significance (p = 0.35 and p = 0.32, respectively). In the ≤12 mo group, panel b, the percentage of hospitalized infants that
were also RSV+ was also progressively decreasing with increasing wGA, without reaching the statistically significance (p = 0.43). In the
>12-24 mo, panel d, the low hospitalization numbers and hospitalized-to-not-hospitalized ratios were associated with a low RSV+
frequency in the <29 and 29- < 32 wGA groups, and no RSV+ hospitalized infants in the 32- < 35 wGA group (Fig. 2d) (p = 0.04)
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frequency, suggesting that, at least in the first year of
age, the most premature infants were more vulnerable
and prone to RSV infection. Very few <29 wGA infants
with a ≤6 month age were included in the study, making
sub-analyses in this group difficult. The instructions for
the management, released after the hospital discharge,
are particularly detailed for the very preterm infants and
their parents are generally very careful in avoiding ex-
posure to any factor that may facilitate infections [26].
The higher vulnerability of infants with ≤6 month age,
belonging to the 29- < 32 and 32- < 35 wGA groups, is
confirmed by the positive hospitalized-to-not hospital-
ized ratios (1.5 and 1.6, respectively), despite the rela-
tively low RSV+ frequency. In the >6-12 month-age
infants, positive hospitalized-to-not hospitalized ratios
were detected in the <29 and 29- < 32 wGA groups, as-
sociated with a relatively high RSV+ frequency, whilst
the 32- < 35 wGA group showed a negative hospitalized-
to-not-hospitalized ratio and a relatively low RSV+ fre-
quency. Interestingly, all the infants of the <29 and 29-
< 32 wGA groups found to be RSV+ were hospitalized.
Therefore not only a high vulnerability, but also an ele-
vated predisposition to RSV infection seem to
characterize the more premature infants in the second
semester of life, when the risk of hospitalization seems
to be particularly related to a more severe viral infection,
i.e. RSV infection, not only in the <29 wGA, but also in
the 29- < 32 wGA group.
The revised recommendations on palivizumab prophy-
laxis for RSV of the Italian Neonatology Society (Società
Italiana di Neonatologia, SIN) recognize that is difficult
to establish a gestational age “threshold” differentiating
between high and low risk in premature neonates of less
than 32 weeks GA [27]. It is undeniable that, as stated
by the SIN recommendations and as also demon-
strated by the present report, risks of RSV-related
Fig. 3 Data from the “Osservatorio” database: comparison between hospitalized (H+) and not hospitalized (H−) children. a On the ordinate, the
number of H+ and H− infants evaluated with a chronological age ≤6 months (mo) are shown and, on the abscissa, the three weeks’ gestational
age (wGA) groups. The H+-to- H− ratios in the three wGA groups are also included in the figure (*). Positive hospitalized-to-not-hospitalized ratios
were detected in all wGA groups, with no statistically significant difference (p = 0.94). b On the ordinate the percentage of H+ and H− infants that
were RSV+ or RSV- are shown and, on the abscissa, the three wGA groups. c and d. The same data in children evaluated with a chronological
age 6- > 12 mo are shown
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hospitalization decrease as gestational age increases
and that the majority of hospitalizations because of
RVS infection occurred during the first six months
of life [27]. In relation to RSV prophylaxis, the SIN
document recommends palivizumab for infants with
<29 wGA and age ≤12 months at the beginning of
the epidemic season, with a level of evidence II and
a strength of recommendation A [27]. For infants
with 29–35 wGA and age ≤12 months at the begin-
ning of the epidemic season, with a level of evidence
IV and a strength of recommendation B, the SIN
document suggests to take in consideration palivizu-
mab prophylaxis in presence of risk conditions
predisposing to severe infections and/or need for
hospitalization [27–31].
Evaluating preterm infants with ≤6 month of age in the
Osservatorio database, we found positive hospitalization
ratios both in the 29- < 32 and 32- < 35 wGA groups,
whilst in the older infants (>6–12 month-age), only the
29- < 32 wGA group, but not the 32- < 35 wGA group,
showed positive hospitalization ratios, with a 50 % RSV+
frequency. Evaluating the ≤12 and the >12 month-age
groups it was clear that the trend in hospitalized-to-not
hospitalized ratios showed a progressive decrease not only
with increasing wGA but also increasing chronological
age. Indeed in the older children, a positive ratio was de-
tected only in the most premature group, the <29 wGA.
The major limitations of the present study are: a) the
retrospective nature of the study but, we had no other
options, since we wanted to evaluate data collected in
years when palivizumab prophylaxis for RSV disease in
premature infants was not widespread in our country; b)
the low number of children born before <35 wGA in-
cluded in this report, and the impossibility to include
other young children in the evaluation of data related to
a retrospective study, give reason for the lack of statis-
tical significance, when the different groups and sub-
groups (wGA, age and risk factors) were compared; c)
the number of children enrolled in the database could
not be adjusted for the distribution of premature infants
in the general population since we could not find the
“live birth certificates” of all the Italian regions related to
the 5 years of the study period.
Conclusions
With the above limitations, the data on the hospitalized-
to-not-hospitalized ratios and on RSV+ frequency in the
first but also in the second semester of life, seem to
show a remarkable vulnerability of the 29- < 32 wGA
group infants. Although further studies are needed to
identify risk factors that may increase the risk of severe
RSV-induced ALRI in this population, the results of this
retrospective analysis may be useful for prophylaxis
planning, at least in our country.
“Osservatorio VRS” study sites
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Azienda Ospedaliera G. Salesi, Ancona; Istituto G.
Gaslini, Genova; Ospedale San Paolo, Milano; Ospedale
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Burlo Garofolo, Trieste; Ospedale Infantile Anna Meyer,
Firenze; Presidio Ospedaliero Annunziata, Cosenza;
Presidio Ospedaliero Garibaldi, S. Luigi, S. Curro, Ascoli
Tomaselli, Catania; Ospedale Maggiore, Bologna;
Ospedale Civile di Legnano, Legnano.
Abbreviations
ALRI: acute lower respiratory tract infection; RSV: respiratory syncytial virus;
wGA: week gestational age.
Competing interests
Dr. Silvestri and Dr. Rossi served as a consultant for AbbVie S.r.l and Dr.
Marando, Costanzo and di Luzio Paparatti are employees of AbbVie and may
own AbbVie stocks options.
Authors’ contributions
MS, FM, AMC, UdLP and GAR made substantial contributions to conception
and design and acquisition. MS, FM and GAR made substantial contributions
to analysis and interpretation of data. MS, FM and GAR were involved in
drafting the manuscript. MS, FM, AMC, UdLP and GAR revised critically the
manuscript for important intellectual content and gave final approval of the
version to be published. MS, FM, AMC, UdLP and GAR agreed to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately
investigated and resolved. All the authors read and approved the final
manuscript.
Disclosure status
Dr. Silvestri and Dr. Rossi served as a consultant for AbbVie S.r.l and Dr.
Marando, Costanzo and di Luzio Paparatti are employees of AbbVie and may
own AbbVie stocks options. The design, study conduct, and financial support
for the original Osservatorio clinical trial was provided by AbbVie. AbbVie
participated in the interpretation of data, review, and approval of the
publication.
Author details
1Pediatric Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto
Giannina Gaslini, Genoa, Italy. 2AbbVie, Medical Department, Campoverde di
Aprilia (LT), Campoverde di Aprilia (Latina), Italy.
Received: 5 February 2016 Accepted: 11 April 2016
References
1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al.
The burden of respiratory syncytial virus infection in young children. N Engl
J Med. 2009;360:588–98.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and
reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–6.
3. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al.
Global burden of acute lower respiratory infections due to respiratory
syncytial virus in young children: a systematic review and meta-analysis.
Lancet. 2010;375:1545–55.
4. Boyce TG, Mellen BG, Mitchel Jr EF, Wright PF, Griffin MR. Rates of
hospitalization for respiratory syncytial virus infection among children in
Medicaid. J Pediatr. 2000;137:865–70.
5. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial
virus-associated hospitalizations among infants and young children in the
United States, 1997–2006. Pediatr Infect Dis J. 2012;31(1):5–9.
Silvestri et al. Italian Journal of Pediatrics  (2016) 42:40 Page 7 of 8
6. Berger TM, Aebi C, Duppenthaler A, Stocker M, Swiss Pediatric Surveillance
Unit. Prospective population-based study of RSV-related intermediate care
and intensive care unit admissions in Switzerland over a 4-year period
(2001–2005). Infection. 2009;37:109–16.
7. Soilly AL, Ferdynus C, Desplanches O, Grimaldi M, Gouyon JB. Paediatric
intensive care admissions for respiratory syncytial virus bronchiolitis in
France: results of a retrospective survey and evaluation of the validity
of a medical information system programme. Epidemiol Infect.
2012;140:608–16.
8. Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, et al.
Palivizumab prophylaxis of respiratory syncytial virus disease in
2000–2001: results from The Palivizumab Outcomes Registry.
Pediatr Pulmonol. 2003;35:484–9.
9. American Academy of Pediatrics. Committee on Infectious Disease: Policy
statement – modified recommendations for use of palivizumab for prevention
of respiratory syncytial virus infections. Pediatrics. 2009;124:1694–701.
10. Carbonell-Estrany X, Figueras-Aloy J, Law BJ, Infección Respiratoria Infantil
por Virus Respiratorio Sincitial Study Group, Pediatric Investigators
Collaborative Network on Infections in Canada Study Group. Identifying risk
factors for severe respiratory syncytial virus among infants born after 33
through 35 completed weeks of gestation: different methodologies yield
consistent findings. Pediatr Infect Dis J. 2004;23:S193–201.
11. Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, et
al. Risk factors for severe RSV-induced lower respiratory tract infection over
four consecutive epidemics. Eur J Pediatr. 2007;166:1267–72.
12. Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, et al.
Inter-society consensus document on treatment and prevention of
bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40:65.
13. American Academy of Pediatrics Committee on Infectious Diseases;
American Academy of Pediatrics Bronchiolitis Guidelines Committee.
Updated guidance for palivizumab prophylaxis among infants and young
children at increased risk of hospitalization for respiratory syncytial virus
infection. Pediatrics. 2014;134:e620–38.
14. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione
delle malattie da virus respiratorio sinciziale (VRS). Aggiornamento 2004.
Redatto dal Consiglio Direttivo della Società Italiana di Neonatologia.
Quaderni ACP. 2004;11:262–5.
15. Lanari M, Giovannini M, Giuffré L, Marini A, Rondini G, Rossi GA, et al.
Prevalence of respiratory syncytial virus infection in Italian infants
hospitalized for acute lower respiratory tract infections, and association
between respiratory syncytial virus infection risk factors and disease severity.
Pediatr Pulmonol. 2002;33:458–65.
16. Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, et al. Four year
incidence of respiratory syncytial virus infection in infants and young
children referred to emergency departments for lower respiratory tract
diseases in Italy: the “Osservatorio VRS” Study (2000–2004). New Microbiol.
2006;29:35–43.
17. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial
virus monoclonal antibody, reduces hospitalization from respiratory
syncytial virus infection in high risk infants. Pediatrics. 1998;102:531–7.
18. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al.
Respiratory syncytial virus-associated hospitalizations among children less
than 24 months of age. Pediatrics. 2013;132(2):e341–8.
19. Zhou H, Thompson WW, Viboud CG, Viboud CG, Ringholz CM, Cheng PY, et
al. Hospitalizations associated with influenza and respiratory syncytial virus
in the United States, 1993–2008. Clin Infect Dis. 2012;54:1427–36.
20. Fryzek JP, Martone WJ, Groothuis JR. Trends in chronologic age and infant
respiratory syncytial virus hospitalization: an 8-year cohort study. Adv Ther.
2011;28:195–201.
21. Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Hospitalization
for respiratory syncytial virus in the paediatric population in Spain.
Epidemiol Infect. 2003;131:867–72.
22. Weigl JA, Puppe W, Schmitt HJ. Incidence of respiratory syncytial virus-
positive hospitalizations in Germany. Eur J Cli Infect Dis. 2001;20:452–9.
23. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
Respiratory syncytial virus and premature infants born at 32 weeks’
gestation or earlier: hospitalization and economic implications of
prophylaxis. Arch Pediatr Adolesc Med. 2000;154(1):55–61.
24. Lanari M, Prinelli F, Adorni F, Di Santo S, Vandini S, Silvestri M, Musicco M.
Risk factors for bronchiolitis hospitalization during the first year of life in a
multicenter Italian birth cohort. Ital J Pediatr. 2015;41:40.
25. Ministero della salute Italiano. Certificato di assistenza al parto (CeDAP).
Analisi dell’evento nascita - Anno 2010. www.salute.gov.it/portale/
documentazione. Accessed 15 Jan 2016.
26. Stark AR, Adamkin DH, Batton DG, Bell EF, Bhutani VK, Denson SE, et al.
Hospital discharge of the high-risk neonate. American Academy of
Pediatrics Committee on Fetus and Newborn. Pediatrics. 2008;122:1119–26.
27. Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, et al. Revised
recommendations concerning palivizumab prophylaxis for respiratory
syncytial virus (RSV). Ital J Pediatr. 2015;41:97.
28. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M, et
al. European risk factors’ model to predict hospitalization of premature
infants born 33–35 weeks’ gestational age with respiratory syncytial virus:
validation with Italian data. J Matern Fetal Neonatal Med. 2011;24:152–7.
29. Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L, Dutch RSV
Neonatal Network. Prospective validation of a prognostic model for
respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter
birth cohort study. PLoS One. 2013;8:e59161.
30. Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus
disease: passive, active immunisation and new antivirals. Arch Dis Child.
2014;99:469–73.
31. Figueras Aloy J, Carbonell Estrany X, Comité de Estándares de la SENeo.
Update of recommendations on the use of palivizumab as prophylaxis in
RSV infections. An Pediatr (Barc). 2015;82:199.e1–2.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Silvestri et al. Italian Journal of Pediatrics  (2016) 42:40 Page 8 of 8
